Trevi Therapeutics TRVI
NASDAQ TRVI
$17.26 +0.20 (+1.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

Trevi Therapeutics (TRVI) Capital Leases (2023)

Trevi Therapeutics (TRVI) posted quarterly Capital Leases of $31000.0 for Q4 2023, down 50.0% quarter-over-quarter from $62000.0 in Q3 2023.

Analysis

Trevi Therapeutics (TRVI) Capital Leases (2023) Analysis & Trends

Trevi Therapeutics' Capital Leases history runs 1 years deep, the most recent figure standing at $31000.0 for Q4 2023.

  • In Q4 2023, Capital Leases changed N/A year-over-year to $31000.0; the TTM figure through Dec 2023 stood at $31000.0 (changed N/A YoY), while the FY2023 annual figure was $31000.0, changed N/A from the prior year.
  • Capital Leases for Q4 2023 stood at $31000.0, down from $62000.0 in the prior quarter.
  • The five-year high for Capital Leases was $124000.0 in Q1 2023, with the low at $31000.0 in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Trevi Therapeutics 2.71 Bn 2.71 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 31,000.00
Sep 30, 2023 62,000.00
Jun 30, 2023 93,000.00
Mar 31, 2023 124,000.00